Transgene Biotek Balance Sheet Health
Financial Health criteria checks 2/6
Transgene Biotek has a total shareholder equity of ₹107.1M and total debt of ₹140.0M, which brings its debt-to-equity ratio to 130.7%. Its total assets and total liabilities are ₹1.4B and ₹1.3B respectively.
Key information
130.7%
Debt to equity ratio
₹140.01m
Debt
| Interest coverage ratio | n/a |
| Cash | ₹77.00k |
| Equity | ₹107.13m |
| Total liabilities | ₹1.32b |
| Total assets | ₹1.42b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 526139's short term assets (₹11.1M) do not cover its short term liabilities (₹111.4M).
Long Term Liabilities: 526139's short term assets (₹11.1M) do not cover its long term liabilities (₹1.2B).
Debt to Equity History and Analysis
Debt Level: 526139's net debt to equity ratio (130.6%) is considered high.
Reducing Debt: 526139's debt to equity ratio has increased from 23.1% to 130.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 526139 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 526139 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 80.9% per year.